September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Small molecules for targeting nonsense mutations causing ciliopathies
Author Affiliations & Notes
  • Fabian Möller
    Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Ananya Samanta
    Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Inessa Penner
    Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Timor Baasov
    Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry, Technion-Israel Institute of Technology, Haifa, Israel
  • Uwe Wolfrum
    Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Kerstin Nagel-Wolfrum
    Cell and Matrix Biology, Institute of Zoology, Johannes Gutenberg University of Mainz, Mainz, Germany
  • Footnotes
    Commercial Relationships   Fabian Möller, None; Ananya Samanta, None; Inessa Penner, None; Timor Baasov, None; Uwe Wolfrum, None; Kerstin Nagel-Wolfrum, None
  • Footnotes
    Support  German Ministry of Education and Research (E-Rare-2, the ERA-Net for Research on Rare Diseases) “EUR-USH”; FAUN-Stiftung, Nuremberg; Foundation Fighting Blindness (FFB); EU FP7 “SYSCILIA”; Tistou and Charlotte Kerstan Foundation
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 1184. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Fabian Möller, Ananya Samanta, Inessa Penner, Timor Baasov, Uwe Wolfrum, Kerstin Nagel-Wolfrum; Small molecules for targeting nonsense mutations causing ciliopathies. Invest. Ophthalmol. Vis. Sci. 2016;57(12):1184.

      Download citation file:


      © 2017 Association for Research in Vision and Ophthalmology.

      ×
  • Supplements
Abstract

Purpose : Inherited retinal ciliopathies are a genetically heterogeneous group of diseases with no effective cure available so far. Approximately 12% of pathogenic mutations found in patient screenings are nonsense mutations, resulting in premature stop codons (PTCs). Translational read-through inducing drugs (TRIDs) are suppressing PTCs depending on their genetic context, resulting in recovered protein expression. Designer aminoglycosides and the clinically approved Ataluren (PTC124, Translarna) are promising TRIDs. Here we study the susceptibility of different ciliopathy–causing nonsense mutations to translational read-through by miscellaneous TRIDs and compare the retinal toxicity of these compounds.

Methods : To evaluate TRID mediated read-through, we generated constructs coding for nonsense mutations causing ciliopathies such as Usher syndrome, Bardet Biedl syndrome and Senior-Loken syndrome. We analyzed the recovery of protein expression after TRID application in HEK293T cells using quantitative immunofluorescence and Western blot analyses. Interaction assays were performed to validate protein function after translational read-through. We evaluated retinal toxicity of TRIDs by comparing TUNEL-assays of treated versus untreated mouse retina explants.

Results : In cellular disease models we observed recovery of protein expression after TRID application in a dose-dependent manner for all ciliopathy-related nonsense mutations. The functionality of the recovered proteins was validated in interaction assays using known interaction partners. We showed improved biocompatibility for designer aminoglycosides and Ataluren, in comparison to canonical aminoglycosides like gentamicin.

Conclusions : Taken together our data demonstrates excellent biocompatibility of TRIDs, along with substantial read-through efficacies for diverse ciliopathy-causing nonsense mutations. These results emphasize the feasibility of TRIDs as a therapeutic strategy tackling retinal ciliopathies caused by nonsense mutations.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×